Merck (MRK) looks undervalued amid 2028 Keytruda patent fears—strong Q3 results, pipeline wins, and 12x P/E suggest upside.

An Auckland woman who is self-funding treatment for her rare, aggressive breast cancer is fed up after years of asking the ...

ORR for BI-1808 combined with pembrolizumab represents a meaningful improvement over pembrolizumab monotherapy in recurrent ovarian cancer (8% ORR in KEYNOTE-100)The combination demonstrated a ...

ORR for BI-1808 combined with pembrolizumab represents a meaningful improvement over pembrolizumab monotherapy in recurrent ovarian cancer (8% ORR in KEYNOTE-100)The combination demonstrated a favorab ...

Company finalizing preparations for end of January 2026 U.S. FDA Biologics License Application (BLA) submission for OST-HER2 ...

Stage 4 RCC is metastatic, with common spread to lungs, bones, liver, brain, and adrenal glands. Understanding IMDC risk is crucial for treatment planning. Systemic therapies, including combination ...

Merck & Co., Inc. (NYSE:MRK) is included among the 14 Best Pharma Dividend Stocks to Buy in 2026. On December 17, the US Food ...

The health reset that began in India after COVID-19 is no longer just about avoiding illness. It has quietly evolved into ...

Johnson & Johnson and Genmab both used the festive period to junk therapies that haven’t lived up to their promise in the ...

Here, BioSpace looks back at the biggest acquisition deals of 2025. Target: Intra-Cellular Therapies Acquisition date: ...

For decades, cancer patients have been told that shrinking tumors meant accepting brutal side effects as the price of ...

TennRich International Corp., a licensed partner of Energizer, reported strong Black Friday performance for Energizer ...